RT Journal Article
SR Electronic
T1 Genome-wide significant risk loci for mood disorders in the Old Order Amish founder population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.22.22271369
DO 10.1101/2022.02.22.22271369
A1 Humphries, Elizabeth M.
A1 Ahn, Kwangmi
A1 Kember, Rachel L.
A1 Lopes, Fabiana L.
A1 Mocci, Evelina
A1 Peralta, Juan M.
A1 Bipolar Sequencing Consortium
A1 Blangero, John
A1 Glahn, David C.
A1 Goes, Fernando S.
A1 Zandi, Peter P.
A1 Kochunov, Peter
A1 Van Hout, Cristopher
A1 Shuldiner, Alan R.
A1 Pollin, Toni I.
A1 Mitchell, Braxton D.
A1 Bucan, Maja
A1 Hong, L. Elliot
A1 McMahon, Francis J.
A1 Ament, Seth A.
YR 2022
UL http://medrxiv.org/content/early/2022/02/24/2022.02.22.22271369.abstract
AB Background Genome-wide association studies (GWAS) of mood disorders in large case-control cohorts have identified numerous risk loci, yet pathophysiological mechanisms remain elusive, primarily due to the very small effects of common variants.Methods We sought to discover risk variants with larger effects by conducting a genome-wide association study of mood disorders in a founder population, the Old Order Amish (OOA, n=1,672).Results Our analysis revealed four genome-wide significant risk loci, all of which were associated with >2-fold relative risk. Quantitative behavioral and neurocognitive assessments (n=314) revealed effects of risk variants on sub-clinical depressive symptoms and information processing speed. Network analysis suggested that OOA-specific risk loci harbor novel risk-associated genes that interact with known neuropsychiatry-associated genes via gene interaction networks. Annotation of the variants at these risk loci revealed population-enriched, non-synonymous variants in two genes encoding neurodevelopmental transcription factors, CUX1 and CNOT1.Conclusions Our findings provide insight into the genetic architecture of mood disorders and a substrate for mechanistic and clinical studies.Competing Interest StatementDr. Shuldiner and Dr. Van Hout are employees of Regeneron Pharmaceuticals. Dr. Hong has received or plans to receive research funding or consulting fees on research projects from Mitsubishi, Your Energy Systems LLC, Neuralstem, Taisho, Heptares, Pfizer, Sound Pharma, IGC Pharma, Regeneron, and Takeda. Dr. Ament has received research funding from Oryzon Genomics LLC. All other authors declare no biomedical financial interests or potential conflicts of interest.Funding StatementThis study was supported by grants and contracts from the National Institute of Mental Health (U01 MH108148 to L.E.H. and P.K., R01 MH110437 to P.P.Z., U01 MH105630 to D.C.G., U01 MH105632 to J.B.), the Regeneron Genetics Center, the Intramural Research Program of the National Institute of Mental Health (ZIA MH002843 to F.J.M.), and a NARSAD Young Investigator Award from the Brain and Behavior Research Foundation to S.A.A. Most of all, we thank the Amish and Mennonite participants, without whose longstanding partnership this study would not have been possible.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the University of Maryland Baltimore gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenotypic and phenotypic data from the Amish TOPMed study and from AMBiGen are available through the National Institute of Health Database of Genotypes and Phenotypes (phs000956.v1.p1, phs000899.v1.p1). Genotypic and phenotypic data from ACP are available through the NIMH Data Archive (Study #2902). Genotypic and phenotypic data from ASMAD are available through the Coriell Institute for Medical Research.